Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Delstrigo Maintenance in HIV with M184V/I Mutation
NCT06034938Phase 2Recruiting
- Sponsor
- CHU Caen Normandie
- Start
- Feb 2024
- Primary completion
- Apr 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of doravirine in human immunodeficiency virus infection (HIV), sponsored by CHU Caen Normandie. Primary endpoint: Plasma HIV-RNA at 24-week. Started Feb 2024; status: recruiting.
02
Drugs
doravirine
03
Conditions
human immunodeficiency virus infection (HIV)
Beyond the preview
Go deeper on NCT06034938.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06034938.